ACQUIREDT+2
Degnan Chris
UroGen Pharma Ltd · NASDAQ
+4,483 sh
Filed 9 Oct 2026SEC Form 4view source
BlackRock
13F filer
$36.8M
2,193,950 sh
ARK Investment Management
13F filer
$3.7M
101,508 sh
Two Sigma Investments
13F filer
$3.2M
177,901 sh
Polen Capital Management
13F filer
$1.1M
29,615 sh
Degnan Chris
US insider
$80.8K
2,281 sh
Smith Jason Drew
US insider
$64.6K
1,815 sh
Robinson James A. Jr.
US insider
—
2,000 sh
Degnan Chris
UroGen Pharma Ltd · NASDAQ
+4,483 sh
Degnan Chris
UroGen Pharma Ltd · NASDAQ
−2,202 sh · $80.8K
Smith Jason Drew
UroGen Pharma Ltd · NASDAQ
−1,519 sh · $64.6K
Schoenberg Mark
UroGen Pharma Ltd · NASDAQ
+1,667 sh
Schoenberg Mark
UroGen Pharma Ltd · NASDAQ
−871 sh · $37.4K
Smith Jason Drew
UroGen Pharma Ltd · NASDAQ
+3,334 sh
Robinson James A. Jr.
UroGen Pharma Ltd · NASDAQ
+2,000 sh
Schoenberg Mark
UroGen Pharma Ltd · NASDAQ
−60,677 sh · $2.9M
ARK Investment Management
UroGen Pharma Ltd · NASDAQ
101,508 sh · $3.7M
Polen Capital Management
UroGen Pharma Ltd · NASDAQ
29,615 sh · $1.1M